Ultra-sensitive assay services for measurement of biomolecules
PBL InterferonSource now offers 30 ultra-sensitive assays
PBL InterferonSource, a division of Pestka Biomedical Laboratories, based in Piscataway, NJ, US, has expanded its assay services portfolio to include 30 different ultra-sensitive biomolecule assays.
Based on a single-molecule counting (SMCI) technology, these services provide sub-picogram per ml sensitivity for analytes in human serum or plasma.
The background reduction methodology of this detection service extends the linear dynamic range to over 4 logs, allowing high levels of biomarker measurement with minimal dilution in many disease states, the company says.
‘The ability to measure basal levels of cytokines and other biomarkers in the femtogram per ml range will enable far deeper analysis of changes in these biomarkers,’ said Thomas Lavoie, Director of Product Research & Development and Assay Services at PBL. ‘This enhanced understanding of various diseases and the effects of œtreatments will allow earlier project milestone decisions, saving our clients time, money and concern.’
The addition of ultra-sensitive cytokine detection services complements the company’s single-analyte ELISA, cytokine multiplex ELISA, and cell-based activity assay services.
Initial ultra-sensitive assay services by PBL include detection for cytokines such as human IL-17A, IL-17F, IL-17 A/F heterodimer, IL-6, IL-1α, IL-1β, IL-10, IL-15, TNF-α, GLP-1, and biomarkers such as cardiac troponin-I.
